Apertura Gene Therapy

Apertura Gene Therapy is a biotechnology company based in New York City. Founded on innovations originating from the Broad Institute and Harvard University, the company is fueled by a small team of 21 dedicated professionals. With backing from Deerfield Management Company, Apertura is focused on developing next-generation gene therapies. Apertura specializes in engineering adeno-associated virus (AAV) gene therapies. Their innovative approach involves simultaneously modifying the capsid, regulatory elements, and payloads to address the current limitations of genetic medicine. This technology aims to provide new treatment options for debilitating diseases that currently have limited therapeutic choices. Apertura's commitment to scientific advancement is evident in their collaboration with prominent research institutions. Their therapies leverage cutting-edge research from the Broad Institute and Harvard University, pushing the boundaries of gene therapy possibilities. To learn more about Apertura Gene Therapy's groundbreaking work, visit their website at aperturagtx.com.